DDInter1666 DDInter1852
In eliciting its mechanism of action, sildenafil ultimately prevents or minimizes the breakdown of cyclic guanosine monophosphate (cGMP) by inhibiting cGMP specific phosphodiesterase type 5 (PDE5) [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614]. The result of doing so allows cGMP present in both the penis and pulmonary vasculature to elicit smooth muscle relaxation and vasodilation that subsequently facilitates relief in pulmonary arterial hypertension and the increased flow of blood into the spongy erectile tissue of the penis that consequently allows it to grow in size and become erect and rigid [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614]. Interestingly enough, it is precisely via this mechanism why sildenafil was at first researched as a potential treatment
Treprostinil is a stable tricyclic analogue of prostacyclin that promotes the vasodilation of pulmonary and systemic arterial vascular beds and the inhibition of platelet aggregation.[L41855,L41860,L41865] It reduces symptoms in patients with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease.[L41855,L41860] The first agent approved for the treatment of PAH was [epoprostenol], a synthetic prostacyclin that significantly increases patients' quality of life. However, the use of epoprostenol is limited due to its short half-life (3-5 min) and instability at room temperature.[A248770,A248775] The use of more stable alternatives such as treprostinil provides patients with PAH with more treatment options. Treprostinil was approved by the FDA in 2002 for the treatment of pulmonary arterial hypertension. It is available in the following routes of administration: subcutaneous, intravenous, inhaled and oral. The first generic form of treprostinil became available in 2019.
Sildenafil {u} (Compound) binds {v} (Gene) CYP2C9
CYP2C9 {u} (Gene) is bound by {v} (Compound) Treprostinil
Sildenafil {u} (Compound) causes {v} (Side Effect) Palpitations
Palpitations {u} (Side Effect) is caused by {v} (Compound) Treprostinil
Sildenafil {u} (Compound) resembles {v} (Compound) Vardenafil
Vardenafil {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Treprostinil
Sildenafil {u} (Compound) binds {v} (Gene) CYP2C9
CYP2C9 {u} (Gene) is bound by {v} (Compound) Epoprostenol
Epoprostenol {u} (Compound) resembles {v} (Compound) Treprostinil
Sildenafil {u} (Compound) causes {v} (Side Effect) Palpitations
Palpitations {u} (Side Effect) is caused by {v} (Compound) Epoprostenol
Epoprostenol {u} (Compound) resembles {v} (Compound) Treprostinil
Sildenafil {u} (Compound) causes {v} (Side Effect) Bone pain
Bone pain {u} (Side Effect) is caused by {v} (Compound) Indapamide
Indapamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Treprostinil
Sildenafil {u} (Compound) causes {v} (Side Effect) Pulmonary hypertension
Pulmonary hypertension {u} (Side Effect) is caused by {v} (Compound) Tadalafil
Tadalafil {u} may cause a minor interaction that can limit clinical effects when taken with {v} Treprostinil
Sildenafil {u} (Compound) resembles {v} (Compound) Udenafil
Udenafil {u} (Compound) resembles {v} (Compound) Vardenafil
Vardenafil {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Treprostinil
Sildenafil {u} (Compound) resembles {v} (Compound) Vardenafil
Vardenafil {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Epoprostenol
Epoprostenol {u} (Compound) resembles {v} (Compound) Treprostinil
Sildenafil {u} (Compound) binds {v} (Gene) CYP2C9
CYP2C9 {u} (Gene) is bound by {v} (Compound) Piroxicam
Piroxicam {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Treprostinil
Sildenafil (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Treprostinil (Compound)
Sildenafil (Compound) causes Palpitations (Side Effect) and Palpitations (Side Effect) is caused by Treprostinil (Compound)
Sildenafil (Compound) resembles Vardenafil (Compound) and Vardenafil may cause a moderate interaction that could exacerbate diseases when taken with Treprostinil
Sildenafil (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Epoprostenol (Compound) and Epoprostenol (Compound) resembles Treprostinil (Compound)
Sildenafil (Compound) causes Palpitations (Side Effect) and Palpitations (Side Effect) is caused by Epoprostenol (Compound) and Epoprostenol (Compound) resembles Treprostinil (Compound)
Sildenafil (Compound) causes Bone pain (Side Effect) and Bone pain (Side Effect) is caused by Indapamide (Compound) and Indapamide may cause a moderate interaction that could exacerbate diseases when taken with Treprostinil
Sildenafil (Compound) causes Pulmonary hypertension (Side Effect) and Pulmonary hypertension (Side Effect) is caused by Tadalafil (Compound) and Tadalafil may cause a minor interaction that can limit clinical effects when taken with Treprostinil
Sildenafil (Compound) resembles Udenafil (Compound) and Udenafil (Compound) resembles Vardenafil (Compound) and Vardenafil may cause a moderate interaction that could exacerbate diseases when taken with Treprostinil
Sildenafil (Compound) resembles Vardenafil (Compound) and Vardenafil may cause a moderate interaction that could exacerbate diseases when taken with Epoprostenol and Epoprostenol (Compound) resembles Treprostinil (Compound)
Sildenafil (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Piroxicam (Compound) and Piroxicam may cause a moderate interaction that could exacerbate diseases when taken with Treprostinil